Safety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene Alterations | MicrobiomeTrials← Back to trialsNCT06160752
Safety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene Alterations
RecruitingPHASE1INTERVENTIONAL
Trial Details
Start: 2023-11-22Est. Completion: 2027-03
Enrollment target: 40 participants Locations- University of California San Francisco (UCSF), San Francisco, California, United States
- Massachusetts General Hospital, Boston, Massachusetts, United States
- The Ohio State University, Columbus, Ohio, United States
- The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Other microbiome trials you might be interested in
Intrahepatic Cholangiocarcinoma (Icc)Neoadjuvant Therapy
This is a multicenter, single-arm, exploratory clinical study for adults with locally advanced intrahepatic cholangiocar…
Nanjing, ChinaEst. completion Mar 1, 2028
Pancreatic Ductal AdenocarcinomaNon Small Cell Lung CancerColorectal CancerSolid Tumor, AdultG12D Mutated KRAS
This study will assess the safety and efficacy of VS-7375 alone and in combination in patients with advanced solid tumor…
Los Angeles, United StatesEst. completion Dec 2028
Cholangiocarcinoma
Cholangiocarcinoma is a rare and aggressive tumor of the bile duct associated with a poor prognosis and very limited tre…
Augsburg, GermanyEst. completion Dec 2027